Journal of Pharmaceutical and Biomedical Analysis
Corrigendum to “A high-performance liquid chromatography-tandem
mass spectrometry method for the analysis of lifirafenib, a novel RAF
kinase and EGFR inhibitor, in human plasma and urine, and its
application in a clinical pharmacokinetic study” [J. Pharm. Biomed.
Anal. 166 (2019) 20–29]
The authors regret that chemical structures of lifrafenib and
BGB-1006 in Fig. 1 from this paper are need to be corrected.
The authors would like to apologise for any inconvenience
caused.
Please cite this article in press as: X. Yao, et al., Corrigendum to “A high-performance liquid chromatography-tandem mass spectrometry method for the analysis of lifirafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine, and its
application in a clinical pharmacokinetic study” [J. Pharm. Biomed. Anal. 166 (2019) 20–29], J. Pharm. Biomed. Anal. (2019),https://doi.org/10.1016/j.jpba.2019.04.047
ARTICLE IN PRESS G ModelPBA-12627; No. of Pages1
Journal of Pharmaceutical and Biomedical Analysis xxx (2019) xxx–xxx
Contents lists available at ScienceDirectJ ournal of Pharmaceutical and Biomedical Analysisjou rn al h omepage: www.elsevier.com/locate/jpba
CorrigendumCorrigendum to “A high-performance liquid chromatography-tandem
mass spectrometry method for the analysis of lifirafenib, a novel RAF
kinase and EGFR inhibitor, in human plasma and urine, and its
application in a clinical pharmacokinetic study” [J. Pharm. Biomed.
Anal. 166 (2019) 20–29]Xueting Yaoa,b, Ling Songa,b, Yang Liua,b, Huanhuan Wanga,b, Jie Liua,b, Ji Jianga,b,Dongyang Liua,b,∗, Pei Hua,b,∗a Clinical Pharmacology Research Center Phase I Unit, Peking Union Medical College Hospital,Peking Union Medical College and Chinese Academy ofMedical Sciences, Beijing 100032, China b Beijing Key Laboratory of Clinical PK and PD Investigation for Innovative Drugs, Beijing 100032, ChinaThe authors regret that chemical structures of lifrafenib andBGB-1006 in Fig. 1 from this paper are need to be corrected.The authors would like to apologise for any inconveniencecaused.DOI of original article: https://doi.org/10.1016/j.jpba.2018.12.038. Corresponding authors at: Clinical Pharmacology Research Center Phase I Unit,Peking Union Medical College Hospital, Peking Union Medical College and Lifirafenib ChineseAcademy of Medical Sciences, Beijing 100032, China.E-mail addresses: [email protected] (D. Liu), hubei01 [email protected](P. Hu).Fig 1: Product ion spectrum of lifirafenib (A) and BGB-1006 (B).https://doi.org/10.1016/j.jpba.2019.04.0470731-7085/© 2019 Elsevier B.V. All rights reserved.